<a href="https://laohu8.com/S/PRE">Prenetics Global</a> Ltd. Reports 336.5% YoY Revenue Increase in Q1 2025, Raises Full-Year Guidance to $80-100M
Prenetics Global Ltd. has reported its financial results, highlighting a significant quarter-over-quarter growth. The company's Q1 revenue was reported at $5.7 million, with a projected Q2 revenue of $8.5 million, marking a 50% increase. Post-divestment of ACT Genomics, Prenetics now focuses on its three consumer health brands: IM8, CircleDNA, and Europa. The divestment has bolstered Prenetics' financial standing, with pro-forma cash reserves reaching approximately $86 million and pro-forma cash and short-term assets totaling $117 million. The company remains debt-free, enhancing its opportunities for shareholder value. Additionally, Prenetics holds a 35% stake in early cancer detection company Insighta, valued at $70 million. The company is exploring innovative treasury management strategies, including digital asset adoption and Bitcoin treasury strategies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prenetics Global Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-032019), on June 18, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。